QIAGEN and Pfizer Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer

QIAGEN

today announced it has entered into a partnership with Pfizer Inc.

for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer. Financial terms of the agreement were not disclosed. Pfizer's investigational compound, dacomitinib (PF-00299804), is an oral inhibitor of HER-1, HER-2 and HER-4 tyrosine kinases. The HER (human epidermal growth factor receptor) signaling pathway plays a role in the complex process of cell growth and metastasis, making it a target for anti-cancer drugs.